2024年3月21日 · NX-1607是第一个进入临床阶段的CBL-B 抑制剂，目前正在进行一项人体、多中心、开放标签、1a/1b 期剂量递增/扩展试验，以评估药物的安全性、耐受性 ...

2023年11月2日 · By bolstering the effectiveness of inherent T- and NK-mediated anti-tumor responses and enhancing antigen recall, NX-1607 offers potential as a supportive and rejuvenating agent for CAR-T or NK cell therapies in patients with hematologic malignancies who have developed resistance.

The CBL-B inhibitor, NX-1607, acts on multiple immune cells, addressing several antitumor resistance mechanisms that render it a potential next generation IO agent. NX-1607 limits TGF-βand Tregmediated T-cell suppression. NX-1607 increases secretion of pro-inflammatory cytokines in human NK cells.

2022年11月10日 · NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models.

2022年6月2日 · NX-1607 is an oral small molecule inhibitor of CBL-B that has demonstrated anti-tumor activity and long-term survival in murine models as both a single agent and in combination with programmed cell death protein-1 (PD-1) antibodies.

NX-1607 (Compound 23) is an inhibitor of Cbl-b, an E3 enzyme in the ubiquitin-proteasome pathway, with an IC50 value of less than 1 nM. NX-1607 can be used in cancer research [1]. Cbl-b-IN-3 (Compound 23) enhances IL-2 secretion by T-cells stimulated with an anti-CD3 antibody alone or in combination with an anti-CD28 antibody [1].

NX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology Frederick Cohen, Paul Barsanti, Neil Bence, Alexandra Borodovsky, Brandon Bravo, Jilliane Bruffey, Mario Cardozo, Ming Liang Chan, Ganesh Cherala, Matthew Clifton, Thomas Cummins, Ketki Dhamnaskar, Stefan Gajewski, Marilena Gallotta, Jose Gomez-Romo,

A Cbl-b inhibitor, Nx-1607, is currently in phase I clinical trials for advanced solid tumor malignancies. Using a suite of biophysical and cellular assays, we confirm potent binding of C7683 (an analogue of Nx-1607) to the full-length Cbl-b and its N-terminal fragment containing the TKBD-LHR-RING domains.

2023年11月14日 · • NX-1607 is an oral small-molecule inhibitor of CBL- B that enhances innate and adaptive immune responses (Figure 1): −NX-1607 has demonstrated anti-tumor activity and long-term survival in murine models as a

NX-1607是口服可生物利用的Casitas B谱系淋巴瘤B（CBL-B）的小分子抑制剂，在结直肠癌和三阴性乳腺癌的动物模型中均显示出显著的抗肿瘤功效。重要的是，与任何一种单独的药物相比，在这些模型中，NX-1607和抗PD-1抗体的组合均显著提高了中位总生存率。